Abstract 202P
Background
The treatment landscape of metastatic castration-sensitive prostate cancer (mCSPC) has evolved rapidly over past few years. Following publications of several large-scale randomised controlled trials (RCTs) Abiraterone (AA) and Docetaxel (DOC), in addition to androgen deprivation therapy (ADT) have been approved as first line therapies for high risk and high volume mCSPC respectively. In 2019, the picture is further complicated by positive results from TITAN, ENZAMET and ARCHES studies. Both Apalutamide (APA) and Enzalutamide (EZA) have been shown to be superior to placebo (plus ADT) in mCSPC. However, no head to head comparison has been made for these four drugs in first line treatment. We therefore conducted a network meta-analysis to guide the selection of best first line therapy for mCSPC.
Methods
A systematic review of RCTs of AA-/ADT-/APA-/DOC-/EZA-containing treatment regimens in newly diagnosed patients with mCSPC identified seven RCTs. (STAMPEDE arm C and arm G, CHARRTED, GETUG-AFU 15 and LATITUDE, TITAN, ENZAMET and ARCHES trials). We conducted a network meta-analysis with random-effects model under frequentist framework. The reported hazard ratios for overall survival (OS) and progression-free survival (PFS) were incorporated into the model. We used P score to rank the treatments. Treatments having higher P scores are suggested to be more preferred.
Results
Comparing with ADT alone, the hazard ratio (HR) for OS ranged from 0.62 to 0.77 with a highest P score of 0.85 for AA+ADT. For PFS, the HR ranged between 0.38 to 0.63. P Score is again highest at 0.38 for AA+ADT. As exploratory analyses, we compare the OS and PFS of AA +ADT, ENZ+ADT and APA+ADT against DOC +ADT. For OS, HR for AA+ADT is 0.8 while HR for ENZ+ADT and APA +ADT are not statistically significant. For PFS, HR for both ENZ+ADT and AA+ADT are significant (0.62 and 0.61 respectively). AA+ADT has a higher P score than ENZ (0.84 versus 0.81).
Conclusions
Our findings suggest that AA + ADT appears to be more effective than APA-ADT, DOC + ADT, and ENZ+ADT in reducing the risk of death in men with mCSPC and preventing disease progression. This network meta-analysis provides useful guidance to clinicians in choosing the first line therapy in mCSPC patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
371P - Clinical utility of Encyclopedic tumour analysis to treat patients advanced refractory head and neck cancers
Presenter: Rajnish Nagarkar
Session: Poster display session
Resources:
Abstract
372P - Real-world fusion landscape in advanced Chinese pancreatic cancer using next generation sequecing: A multicenter study
Presenter: Yiyu Shen
Session: Poster display session
Resources:
Abstract
373P - Molecular profiling of non-small cell lung cancer (NSCLC) in Asia with targeted next-generation sequencing (NGS): Interim analysis of a co-operative group study (ATORG-001)
Presenter: Aaron Tan
Session: Poster display session
Resources:
Abstract
374P - Circulating tumour DNA (ctDNA) identifies actionable genetic alterations in Middle Eastern and Asian (MEA) patients diagnosed with carcinoma of unknown primary (CUP)
Presenter: Nir Peled
Session: Poster display session
Resources:
Abstract
375P - Whole-exome sequencing of tumour-only samples reveals the association between somatic alterations and clinical features in pancreatic cancer
Presenter: Huixin Lin
Session: Poster display session
Resources:
Abstract
376P - Adoption of molecular testing in breast cancer in a tertiary care center in a developing country
Presenter: Prasanta Dash
Session: Poster display session
Resources:
Abstract
377P - NGS in advanced NSCLC in a developing country: Ready for prime time?
Presenter: Amrith B P
Session: Poster display session
Resources:
Abstract
378P - Germline BRCA1/2 testing: Trend in Tan Tock Seng Hospital Singapore
Presenter: Chia Wei Lim
Session: Poster display session
Resources:
Abstract
379P - Study of germline mutations in high risk cancer patients from a tertiary care center in India
Presenter: Padmaj Kulkarni
Session: Poster display session
Resources:
Abstract
380P - Ventricular–Subventricular zone involvement: A predictive factor for survival in glioblastoma
Presenter: Vibhay Pareek
Session: Poster display session
Resources:
Abstract